Free Trial

Citius Oncology (CTOR) Competitors

Citius Oncology logo
$1.97 +0.02 (+1.03%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.98 +0.01 (+0.51%)
As of 07/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTOR vs. BCAX, ORKA, KURA, ATAI, VALN, SEPN, RAPP, OPT, ATYR, and SIGA

Should you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Bicara Therapeutics (BCAX), Oruka Therapeutics (ORKA), Kura Oncology (KURA), atai Life Sciences (ATAI), Valneva (VALN), Septerna (SEPN), Rapport Therapeutics (RAPP), Opthea (OPT), aTyr Pharma (ATYR), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry.

Citius Oncology vs. Its Competitors

Bicara Therapeutics (NASDAQ:BCAX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

70.5% of Citius Oncology shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bicara Therapeutics presently has a consensus price target of $31.86, suggesting a potential upside of 171.14%. Citius Oncology has a consensus price target of $3.00, suggesting a potential upside of 52.28%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Citius Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Citius Oncology
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicara TherapeuticsN/AN/A-$68MN/AN/A
Citius OncologyN/AN/AN/AN/AN/A

In the previous week, Citius Oncology had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 2 mentions for Citius Oncology and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.82 beat Citius Oncology's score of 1.24 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Bicara Therapeutics Very Positive
Citius Oncology Positive

Bicara Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Bicara TherapeuticsN/A N/A N/A
Citius Oncology N/A -53.88%-18.86%

Summary

Bicara Therapeutics beats Citius Oncology on 8 of the 10 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTOR vs. The Competition

MetricCitius OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$154.39M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.1020.05
Price / SalesN/A288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book3.088.378.665.87
Net IncomeN/A-$55.19M$3.25B$258.55M
7 Day Performance28.76%5.88%4.23%3.74%
1 Month Performance-43.71%17.33%10.52%11.75%
1 Year PerformanceN/A4.42%34.41%18.03%

Citius Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTOR
Citius Oncology
1.7523 of 5 stars
$1.97
+1.0%
$3.00
+52.3%
N/A$154.39MN/A0.00N/APositive News
Analyst Upgrade
Gap Up
BCAX
Bicara Therapeutics
2.0922 of 5 stars
$10.18
+4.8%
$31.86
+213.0%
N/A$555.22MN/A0.0032
ORKA
Oruka Therapeutics
2.7217 of 5 stars
$14.70
+3.3%
$40.38
+174.7%
N/A$550.37MN/A-3.26N/AUpcoming Earnings
Analyst Forecast
KURA
Kura Oncology
4.4987 of 5 stars
$6.35
+1.1%
$24.50
+285.8%
-70.0%$549.72M$53.88M-3.02130Positive News
ATAI
atai Life Sciences
3.321 of 5 stars
$2.72
+3.8%
$9.00
+230.9%
+125.9%$544.92M$1.86M-2.9980News Coverage
VALN
Valneva
1.9691 of 5 stars
$6.32
+4.1%
$15.50
+145.3%
+5.8%$537.79M$186.06M-5.31700News Coverage
Gap Up
SEPN
Septerna
1.4515 of 5 stars
$12.01
+2.4%
$26.75
+122.7%
N/A$535.17M$1.08M0.00N/ANews Coverage
RAPP
Rapport Therapeutics
1.6466 of 5 stars
$14.63
+0.2%
$28.00
+91.4%
-27.7%$534.00MN/A-4.24N/ANews Coverage
OPT
Opthea
0.3324 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+55.0%$524.83M$120K0.008News Coverage
Gap Up
ATYR
aTyr Pharma
2.1633 of 5 stars
$5.53
+4.3%
$20.20
+265.3%
+161.4%$492.17M$230K-6.8353News Coverage
Gap Up
High Trading Volume
SIGA
Siga Technologies
1.9899 of 5 stars
$6.86
+1.3%
N/A-28.7%$490.08M$138.72M10.2440News Coverage
Upcoming Earnings
Options Volume

Related Companies and Tools


This page (NASDAQ:CTOR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners